Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Positive Results From Phase II Trial of CH-1504 in Rheumatoid Arthritis

* Study Successfully Demonstrated Comparable Efficacy of Multiple Doses of CH-1504 to Methotrexate * All Doses of CH-1504 Showed Almost Two-Fold or Greater Reduction in Liver Enzyme...
March 13, 2009 16:15 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350

CHARLOTTE, N.C., March 13, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today, pursuant to Nasdaq Marketplace Rule 4350, that the audit report contained in...
March 04, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Fourth Quarter and Full Year 2008 Results

CHARLOTTE, N.C., March 4, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year 2008 and will host a...
March 02, 2009 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Positive Preliminary Results of Phase II Study of Droxidopa in Intradialytic Hypotension

* Statistically Significant Reduction (87.5%) in the Number of Patients Requiring Early Termination of Hemodialysis Sessions * Statistically Significant Decrease in the Severity of...
February 25, 2009 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2008 Results

CHARLOTTE, N.C., Feb. 25, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter and full year results for the period ended...
February 17, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Findings From Open-Label Titration Phase of Pivotal Phase III Trials

* Data from Study 302 continued to demonstrate robust effect with mean reduction in symptomatic score of 4.2 units and increase of 25mmHg in standing systolic blood pressure * Preliminary...
February 11, 2009 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present At the ROTH 21st Annual OC Growth Stock Conference On Monday, February 16, 2009

CHARLOTTE, N.C., Feb. 11, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the ROTH 21st Annual OC Growth Stock Conference at 3:20 PM PT on...
January 28, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Initiates Phase II Trial of Droxidopa in Fibromyalgia

CHARLOTTE, N.C., Jan. 28, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has initiated a Phase II trial of Droxidopa, a synthetic precursor of norepinephrine, both...
November 19, 2008 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Completes Enrollment in Phase II Trial of Droxidopa in Intradialytic Hypotension

CHARLOTTE, N.C., Nov. 19, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed patient enrollment in its Phase II trial of Droxidopa, an orally active...
November 13, 2008 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Initiates Phase I Clinical Trial of CH-4051

CHARLOTTE, N.C., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has begun dosing volunteers in the single ascending dose (SAD) study of its Phase I clinical...